Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Allegan, Mich.-based generics firm saw "strong sales of loratadine D-24, the store brand equivalent to Claritin D-24; had strong initial shipments of loratadine syrup and loratadine quick-dissolve tablets; and experienced growth in the vitamin category" during the third quarter ended March 27, Perrigo CEO David Gibbons reports in an April 23 earnings call. Overall net sales grew 14% to $230.7 mil. compared to the year-ago quarter. Results were driven by "new products launched earlier in the year, new products shipping in the current period, and revenue from Peter Black Pharmaceuticals, a UK-based nutritional business acquired in December 2003"...
You may also be interested in...
Perrigo Children’s Loratadine Syrup Pulled: 2.8 Mil. Bottles In Play
Perrigo is recalling all lots of loratadine syrup from retailer and wholesaler channels because of manufacturing issues
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.